Sharon Shacham
CIK: 0001588438
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (3 total)
- Jun 17, 2026ACRV
Acrivon Therapeutics, Inc.
Award(A)DirectStock Option (Right to Buy)
20.3K shares- - May 18, 2026ACRV
Acrivon Therapeutics, Inc.
Award(A)Direct9.4K shares- - Jun 13, 2025ACRV
Acrivon Therapeutics, Inc.
Award(A)DirectStock Option (Right to Buy)
20.3K shares-
1-3 of 3 transactions
About Shacham Sharon
Shacham Sharon (SEC CIK 0001588438) files insider reports with the SEC as Director of Acrivon Therapeutics, Inc. (ACRV) and Director of Nasus Pharma Ltd (NSRX).
Signal8 holds 4 ownership filings by Shacham Sharon (1 Form 3, 3 Form 4), filed between Jun 17, 2025 and Jun 22, 2026. Those filings report 3 transactions, from Jun 13, 2025 to Jun 17, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Shacham Sharon's filings is in WATERTOWN, MA.
Recent filings by Shacham Sharon
Other insiders filing for Acrivon Therapeutics, Inc. (ACRV)
- Miller Mary, Chief Legal Officer
- Levin Michaela, Chief Business Officer
- Blume-Jensen Peter, President and CEO
- Peterson Katharine, Chief Accounting Officer
- Gamelin Erick, Chief Development Officer
- Devroe Eric, Chief Operating Officer